Risk for renal cell carcinoma in chronic hepatitis C infection

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 4, 2010, Pages 1066-1073

  Gordon, Stuart C ^a   Moonka, Dilip ^a   Brown, Kimberly A ^a   Rogers, Craig ^b   Huang, Mary Ann Y ^a   Bhatt, Neal ^c   Lamerato, Lois ^c  

^a Division of Gastroenterology   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; RIBAVIRIN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER REGISTRY; CANCER RISK; ETHNICITY; FEMALE; GROUPS BY AGE; HEALTH CARE SYSTEM; HEPATITIS C; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SEROLOGY; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; COHORT STUDIES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; RISK FACTORS; YOUNG ADULT;

EID: 77950845379     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-1275     Document Type: Article

References (26)

1. World Health Organization. Hepatitis C. Fact Sheet No. 164. Revised October 2000. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed November 10, 2008.
2. Kamar N, Izopet J, Alric L, Guilbeaud-Frugier C, Rostaing L. Hepatitis C virus-related kidney disease: an overview. Clin Nephrol 2008;69: 149-160 (Pubitemid 351351061)
3. Sansonno D, Lauletta G, Montrone M, Grandaliano G, Schena FP, Dammacco F. Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures Isolated with laser capture microdissection. Clin Exp Immunol 2005;140:498-506. (Pubitemid 40813960)
4. Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 2007;297:2010-2017 (Pubitemid 46740353)
5. Pal S, Sullivan DG, Kim S, et al. Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: Implications of HCV lymphotropism. Gastroenterology 2006;130:1107-1116
6. Chow WH, Devesa SS, Warren JL, Fraumeni JF, Jr. Rising incidence of renal cell cancer in the United States. JAMA 1999;281:1628-1631
7. Mathew A, Devesa SS, Fraumeni JF, Jr., Chow W-H. Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev 2002;11:171-178
8. La Vecchia C, Negri E, Levi F. Increasing incidence of renal cell cancer. JAMA 1999;282:2120-2121
9. Falebita OA, Mancini S, Kiely E, Comber H. Rising incidence of renal cell carcinoma in Ireland. Int Urol Nephrol 2009;41:7-12.
10. Marumo K, Kanayama H, Miyao N, et al. Prevalence of renal cell carcinoma: a nation-wide survey in Japan, 2002. Int J Urol 2007;14:479-482
11. Di Micco B, Di Micco P. HCV and renal cell carcinoma: a new insight between HCV and oncogenesis? Report of five cases. Experimental Oncology 2003;25:77-78 (Pubitemid 36528271)
12. Fayek S, Moore D, Bortecen KH, et al. Liver transplantation in the setting of extra-hepatic malignancy: two case reports. Transplant Proc 2007;39:3512-3521
13. Garcia JH, Coelho GR, Cavalcante FP, et al. Synchronous hepatocellular carcinoma and renal cell carcinoma in a liver transplant recipient: a case report. Transplantation 2007;84:1713.
14. Rifkin SI. Thirty-seven uninterrupted years of hemodialysis: a case report. Medscape J Med 2008;10:231.
15. Thompson RH, Ordonez MA, lasonos A, et al. Renal cell carcinoma in young and old patients-is there a difference? J Urol 2008;180:1262-1266
16. Stafford HS, Saltzstein SL, Shimasaki S, Sanders C, Downs TM, Robins Sadler G. Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. J Urol 2008;179:1704-1708
17. Matsuya M, Abe T, Tosaka M, et al. The first case of polymyositis associated with interferon therapy. Intern Med 1994;33:806-808
18. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-714
19. Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health 1996;86:642-654
20. Vajdic CM. Cancer incidence before and after kidney transplantation. JAMA 2006;296:2823-2831
21. Stewart JH. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol 2003;14:197-207.
22. Tsui Jl, Vittinghoff E, Shlipak MG, et al. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med 2007;167:1271-1276 (Pubitemid 46998498)
23. Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus Induces hepatocellular carcinoma in transgenic mice. Nat Med 1998;4:1065-1067 (Pubitemid 28417341)
24. Tanaka N, Moriya K, Kiyosawa K, Koike K, Gonzalez FJ, Aoyama T PPARα activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest 2008; 118:683-694 (Pubitemid 351206557)
25. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005;1:CD001425.
26. Kawamura Y, lkeda K, Arase Y, et al. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med 2007;120:1034-1041 (Pubitemid 350166219)